![]() Ischemic heart disease (IHD) is a significant cause of morbidity and mortality in Western society. This review summarizes efforts to date in targeting mitochondria for ischemic heart disease and cardiomyopathy therapy and outlines emerging drug targets in this field. ![]() Notably, there are a number of overlapping therapies for both these diseases, and as such novel therapeutic options for one condition may find use in the other. As such, the mitochondrion is a potential untapped target for new ischemic heart disease and cardiomyopathy therapies. However, despite promising mitochondria-targeted drugs emerging from the laboratory, very few have successfully completed clinical trials. Mitochondrial dysfunction plays a key role in the pathogenesis of ischemia and reperfusion injury and cardiomyopathy. Although interventions, such as thrombolysis and percutaneous coronary intervention, have proven efficacious in ischemia and reperfusion injury, the underlying pathological process of ischemic heart disease, laboratory studies suggest further protection is possible, and an expansive research effort is aimed at bringing new therapeutic options to the clinic. Ischemic heart disease is a significant cause of morbidity and mortality in Western society. ![]()
0 Comments
Leave a Reply. |